Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.20 USD
-0.07 (-5.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NKTR 1.20 -0.07(-5.51%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
Nektar initiated with bullish view at Rodman & Renshaw
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024